JIMCO (Jameel Investment Management Company) is the global investment arm of the Jameel family. JIMCO actively invests in innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of core industries driving the global economy.
Through two dedicated funds, JIMCO Life Sciences and the JIMCO Technology Fund, the Company’s investments span medical and healthcare industries, from pharmaceuticals and vaccines to cutting-edge medical technology, along with emergent technologies across fintech, insurtech, electric vehicles and future mobility solutions.
Abdul Latif Jameel Health
Abdul Latif Jameel Health reflects the Jameel Family’s long-established commitment to innovating for a better future through Community Jameel, an international organization supporting science and technology-led solutions to global challenges. Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) in September 2018 – which has rapidly become the very epicenter of AI and healthcare at MIT – and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) co-founded with Imperial College London, in October 2019, using novel data analytics to reduce global risk of preventable disease strengthening health systems in the most fragile settings.
Abdul Latif Jameel Health takes this commitment into the commercial environment addressing tangible real-world needs. It is focused on health care inclusion in the global south, accelerating access to modern medical care for those who need it most by opening up/growing new markets for distribution of existing solutions and investing in the future of MedTech.